Carl Icahn
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
Icahn has successfully pushed for changes at Time Warner (NYSE: TWX) and Temple-Inland (NYSE: TIN), among others. Icahn won board seats at Motorola (NYSE: MOT) after first failing.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
In early, 2008 Icahn activist target BEA Systems (Nasdaq: BEAS) was sold to Oracle (Nasdaq: ORCL). Icahn held a 13% stake in BEA.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
-
-
-
-
-
-
-
Eli Lilly & Co. (LLY) Reports 50% of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Phase 3 Study
-
-
-
-
-
-
-
Lilly (LLY) Announces Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn's Disease in 52-Week Phase 2 Trial
-
-
-
-
-
-
-
Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
-
-
-
-
-
-
-
Wall Street Hubbub 7/21: Traders Nervous Ahead NFLX/BIDU Results, Dimon & Blankfein Not Welcome at FinReg Signing, Bernanke Set to Testify, BIIB/LLL/DTG In the Rumor Mill
-
-
-
-
-
-
-
Analyst Expects Immediate $70/Share Offer for ImClone (IMCL) from Bristol-Myers Following News
11,355 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All